Serna Bio
Make every gene druggable with AI-designed RNA-targeting small molecules
Serna Bio is a drug discovery company that uses AI and machine learning to design small molecules targeting RNA rather than proteins. Their platform leverages synthetic biology, ML, and multiplexed screening to modulate translation and splicing for hard-to-drug targets. They aim to expand the druggable genome by treating RNA as a therapeutic target for diseases with high unmet medical need.
Serna Bio's AI platform rationally designs selective small molecules that target RNA structures involved in translation and splicing, bypassing the need to target proteins directly.
pharmaceutical researchers and biotech partners seeking RNA-targeted therapies
Background.
- Status
- unknown
- Business model
- unknown
- Company
- Serna Bio
Similar projects.
Editorial take on the space this project sits in — momentum signals, adjacent moves, our call on whether the wedge is real. Get pinged when we publish a new read or when the landscape shifts.
Have a take on this space?
Tell us what you’d build differently, where you think the incumbents miss, or what we’ve gotten wrong about this project. Comments + reactions are coming soon.